The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to Plasmodium falciparum parasite resistance
Abstract
We report an acylguanidine preclinical candidate with pharmacological features compatible with single low-dose malaria cure.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jul 21, 2021
- Source ID
- 10.1126/scitranslmed.abg6013
Entities
People
- Alain Pellet
- Anne-Catrin Uhlemann
- Benjamin Blasco
- Charisse Flerida A Pasaje
- Cécile Pascal
- David A. Fidock
- Delphine Baud
- Didier Leroy
- Elie Giraud
- Fanny Escudié
- Francisco Javier Gamo
- Gilles Courtemanche
- Gilles Tuffal
- Grennady Wirjanata
- Guillaume Louit
- Iñigo Angulo-Barturen
- Jacquin C Niles
- Jade Bath
- James M Murithi
- Jayan T. Joseph
- Jean Michel Augereau
- Jean-michel Guillon
- Jutta Marfurt
- Jérôme Menegotto
- Kelly Rubiano
- Laura M. Sanz
- Laurent Fraisse
- Laurent Sallé
- Lidiya Bebrevska
- Marie Françoise Nicolas
- Marie‐José Cabanis
- Marı́a Belén Jiménez-Dı́az
- Melanie Rouillier
- Michel Doubovetzky
- Mohammed H Cherkaoui-Rbati
- Nadir Bessila
- Nathalie Gobeau
- Nina F Gnädig
- Patrick Tumwebaze
- Paul Désert
- Philip J Rosenthal
- Richard Price
- Rintis Noviyanti
- Rita Merino
- Roland A. Cooper
- Sachel Mok
- Sergio Wittlin
- Shivendra Singh
- Simon Campbell
- Sridevi Bashyam
- Sylvie Klieber
- Tanguy Bozec
- Tomas Yeo
- Vermat Thierry
- Xavier Boulenc
Organizations
- Charles Darwin University
- Columbia University
- Dominican University of California
- Eijkman Institute for Molecular Biology
- GSK
- Gates Foundation
- Human Frontier Science Program
- Infectious Diseases Research Collaboration
- Mahidol University
- Massachusetts Institute of Technology
- Medicines for Malaria Venture
- National Institute of Allergy and Infectious Diseases
- Sanofi
- Sanofi Pasteur
- Swiss Tropical and Public Health Institute
- United States Department of Defense
- University of Basel
- University of California, San Francisco
- University of Oxford